Wide Ranks

AUTL

Autolus Therapeutics plc

3.27

Top Statistics
Market Cap 870 M Forward PE -4.08 Revenue Growth 0.00 %
Current Ratio 13.69 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.50 Enterprise / Revenue 50.96 Price To Sales Trailing12 Months 86.24
Profitability
Profit Margins 0.00 % Operating Margins -2113.54 %
Balance Sheet
Total Cash 657 M Total Cash Per Share 2.47 Total Debt 301 M
Total Debt To Equity 63.14 Current Ratio 13.69 Book Value Per Share 1.79
All Measures
Short Ratio 289.00 % Message Board Id finmb_562879769 Shares Short Prior Month 8 M
Return On Equity -0.8220 City London Uuid da5466ad-c9a9-3bae-a4e5-c7afee3582d0
Previous Close 3.10 First Trade Date Epoch Utc 1 B Book Value 1.79
Total Debt 301 M Volume 1 M Price To Book 1.82
Fifty Two Week Low 2.69 Total Cash Per Share 2.47 Total Revenue 10 M
Shares Short Previous Month Date 1 B Target Median Price 10.50 Max Age 86400
Recommendation Mean 1.20 Sand P52 Week Change 0.3133 Operating Margins -2113.54 %
Target Mean Price 10.45 Net Income To Common -270227008 Short Percent Of Float 0.0317
Implied Shares Outstanding 266 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 2 M Average Volume10days 2 M Total Cash 657 M
Next Fiscal Year End 1 B Revenue Per Share 0.0430 Held Percent Insiders 0.1809
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 3.10 Target Low Price 7.60 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.74 Open 3.15 Free Cashflow -171182752
Dividend Yield 0.00 % Return On Assets -0.2161 Time Zone Short Name EST
Trailing Eps -1.22 Day Low 3.13 Address1 The Mediaworks
Shares Outstanding 266 M Price Hint 4 Target High Price 13.00
Website https://www.autolus.com 52 Week Change -0.2360 Average Volume 1 M
Forward Eps -0.7300 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1252.20 % Is_sp_500 False Regular Market Day High 3.38
Profit Margins 0.00 % Debt To Equity 63.14 Fifty Two Week High 7.45
Day High 3.38 Shares Short 6 M Regular Market Open 3.15
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 50.96
Revenue Growth 0.00 % Shares Percent Shares Out 0.0235 Operating Cashflow -193170000
Currency USD Time Zone Full Name America/New_York Market Cap 870 M
Is_nasdaq_100 False Zip W12 7FP Quote Type EQUITY
Industry Biotechnology Long Name Autolus Therapeutics plc Regular Market Day Low 3.13
Held Percent Institutions 0.7621 Current Price 3.27 Address2 191 Wood Lane White City
Enterprise To Ebitda -2.50 Financial Currency USD Current Ratio 13.69
Gross Margins -223.30 % Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United Kingdom Float Shares 131 M Two Hundred Day Average 4.37
Enterprise Value 514 M Price To Sales Trailing12 Months 86.24 Forward PE -4.08
Regular Market Volume 1 M Ebitda -205863008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.

The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.

Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.